1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH Director's New Innovator Award (DP2) is sponsored by NIH Common Fund. Supports unusually innovative research from early career investigators who are within 10 years of their terminal degree or within 10 years of completing their clinical residency, who have not yet received a research project grant (R01) or equivalent peer-reviewed grant.
Get alerted about grants like this
Get emailed when new opportunities from “NIH Common Fund” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIH Director's New Innovator Award | NIH Common Fund NIH Director's New Innovator Award NIH Director's New Innovator Award FY2026 NIH Director’s New Innovator Award informational video Part of the High-Risk, High-Reward Research program, the NIH Director's New Innovator Award supports early career investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the NIH mission.
Part of the High-Risk, High-Reward Research program , the award supports early career investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the NIH mission.
Must have Early Stage Investigator status (completed doctoral degree or postgraduate clinical training within last 10 years and never received a substantial NIH independent research award) No preliminary data required Minimum of 25% research effort $475,000/year for 5 years See the Award Overview for more information. Applications due August 17, 2026.
Application & Award Guide Recent News & Announcements Harnessing Immune Cells to Deliver Brain Implants Without Surgery How Cellular Receptors Could Be Targeted to Treat Disease Nanoparticle Breakthrough Shows Potential for Treating Pre-Eclampsia Technological Improvements Propel Kidney Disease Research Forward This page last reviewed on
According to the current listing, eligibility includes: Early career investigators within 10 years of their terminal degree or clinical residency, without prior R01 or equivalent funding. Confirm the full requirements in the official notice before applying.
Applications for NIH Director's New Innovator Award (DP2) are due August 17, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIH Director's New Innovator Award (DP2) is funded by NIH Common Fund. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward interdisciplinary projects that leverage AI, machine learning, and advanced data science to address pressing questions in biomedical and public health research. It seeks to advance fundamental scientific and engineering contributions across disciplines to solve key health problems.
The NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleAvoid common NIH grant proposal mistakes including vague specific aims, weak methodology, and poor budget justification that lead to rejection.
Read articleThe NIH Director's New Innovator Award (DP2, RFA-RM-27-002) closes August 17, 2026, offering roughly 30 Early Stage Investigators up to $475,000 in direct costs a year for five years — $2.375 million total — to pursue bold ideas without the preliminary data a standard R01 demands. Here is how the High-Risk, High-Reward program actually evaluates applications, who qualifies, and why the usual R01 instincts will sink you.
Read article